Tenecteplase shows no significant difference in serious adverse event distribution compared to alteplaseTrial shows tenecteplase is as safe as alteplase for stroke

This multicenter Phase 3 randomized controlled trial provided a post-hoc analysis of the safety profiles of two thrombolytic agents, tenecteplase and alteplase. The study population consisted of 1577 patients with ischemic stroke who presented within 4.5 hours of symptom onset. The primary outcome was not reported in this specific analysis.

The intervention group received tenecteplase while the comparator group received alteplase. The trial aimed to evaluate safety and tolerability outcomes over a follow-up period of 90 days. Specifically, researchers analyzed serious adverse events (SAEs) and their correlation with clinical scores such as the modified Rankin Scale.

Regarding safety data, 219 patients (13.9%) experienced SAEs. Nervous system disorders were the most common type of SAE, occurring in 58.2% of those cases. This category included stroke worsening (26.7%) and intracranial hemorrhage (25%). Crucially, no significant differences were observed in the distribution of these SAEs when comparing tenecteplase to alteplase.

Secondary outcomes highlighted specific correlations between SAEs and clinical severity. Patients who experienced an SAE had a higher median NIH Stroke Scale score (11) compared to those without an SAE (9), with a p-value < 0.002. Furthermore, the rate of endovascular treatment was significantly higher in patients with SAEs (50.2%) compared to those without (29.2%), with a p-value < 0.001. At the 90-day mark, modified Rankin Scale scores were also higher in patients who experienced an SAE (OR 3.93; 95% CI, 2.78-5.56), with median scores of 4 versus 2.

Several independent predictors for SAEs were identified through multivariate analysis. A baseline NIH Stroke Scale increase per standard deviation was associated with a higher risk (OR 1.2; 95% CI, 1.0-1.5). Large-vessel occlusion was also an independent predictor (OR 1.6; 95% CI, 1.1-2.5). Conversely, the Alberta Stroke Program Early Computed Tomography Score showed a lower risk per point increase (OR 0.9; 95% CI, 0.8-1.0), and cerebral atrophy was associated with higher risk (OR 1.5; 95% CI, 1.1-1.9).

These results compare favorably to existing standards in the field by confirming that tenecteplase does not increase the risk of specific types of complications compared to alteplase. However, it is important to note that this was a post-hoc analysis of an RCT, which may introduce certain biases or limitations in generalizability compared to a primary analysis.

Clinically, these findings support the use of tenecteplase as a viable alternative to alteplase for patients with ischemic stroke presenting within 4.5 hours. The data suggest that the choice between these two thrombolytics does not significantly impact the incidence or type of serious adverse events. Questions remain regarding the long-term functional outcomes beyond 90 days and how specific patient phenotypes might respond differently to each agent in real-world settings.